Pro Medicus Ltd
ASX:PME
Intrinsic Value
The intrinsic value of one
PME
stock under the Base Case scenario is
30.61
AUD.
Compared to the current market price of 164.3 AUD,
Pro Medicus Ltd
is
Overvalued by 81%.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Pro Medicus Ltd.
Fundamental Analysis
PME Profitability Score
Profitability Due Diligence
Score
PME Solvency Score
Solvency Due Diligence
Score
Heightened competition from larger healthcare IT players could erode Pro Medicus’s pricing power and disrupt its pipeline of long-term contracts, especially in the heavily contested U.S. hospital market.
Reliance on a few marquee contracts, including sizeable deals with major hospital networks, poses revenue-concentration risk. Any failure to renew or expand these key partnerships could materially impact the firm’s top line.
Regulatory hurdles and prolonged sales cycles in new geographic regions could delay client onboarding, driving up costs and extending the time needed to realize meaningful returns on international expansion initiatives.
Pro Medicus’s cloud-based imaging software offers faster performance and greater scalability than most legacy systems, giving it a strong competitive advantage in winning high-margin, multi-year contracts with top-tier healthcare providers.
The company has demonstrated consistent growth in recurring revenue tied to usage-based licensing fees, reflecting robust adoption rates and strong stickiness among its existing hospital networks in the U.S. and Europe.
An agile research and development approach, supported by a debt-free balance sheet, enables Pro Medicus to quickly incorporate emerging technologies like AI-driven analytics, expanding its service offerings and creating additional revenue streams.
Balance Sheet Decomposition
Pro Medicus Ltd
Pro Medicus Ltd
Free Cash Flow Analysis
Pro Medicus Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Pro Medicus Ltd
Wall St
Price Targets
PME Price Targets Summary
Pro Medicus Ltd
According to Wall Street analysts, the average 1-year price target for
PME
is 317.39 AUD
with a low forecast of 227.25 AUD and a high forecast of 367.5 AUD.
Dividends
Current shareholder yield for PME is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
PME
stock under the Base Case scenario is
30.61
AUD.
Compared to the current market price of 164.3 AUD,
Pro Medicus Ltd
is
Overvalued by 81%.
